If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
half-year financial results for the six months ended June 30, 2022 on Thursday, August 25, 2022 at 02:00 AM (EDT) / 07:00 AM (BST) / 09:00 AM (EEST).
A virtual briefing and Q&A session for investors, analysts and media will be hosted by Dr. Markku Jalkanen, Chief Executive Officer, and Toni Hänninen, Chief Financial Officer, at 7:00 am (EDT) / 12:00 pm (BST) / 2:00 pm (EEST) on the day of results.
Webcast registration link: https://faron.videosync.fi/2022-halfyear-results
We need a RNS before the presentation else there is no new news although there may well be a better explanation of old news
Hope so
I would prefer a US listing to raise cash. A far larger market to start buying faron shares could breath some life into the stock price.
However I'm not sure if they will have to do a partnership deal with a big pharma, even if all our results are good we may need them to sell the drug to the market.
Or maybe a buyout will just happen?
That latest report seemed to say a bexcombo was the earliest chance of revenue, so maybe the combo side will make an offer?
Faron has announced that it is recruiting staff for its US office in Boston. In addition to clinical research staff, the company has also recruited IR staff. Indeed, the company's management has mentioned an IPO in the US as one possibility for financing the company.
In addition, the company has the possibility of seeking funding from its existing marketplaces on the London AIM and Nasdaq First North. The company said that in summer 2022, it had arranged a directed issue of EUR 5 MEUR, which we understand will cover one third of the EUR 15 MEUR required by the loan agreement. We estimate that Faron will seek to raise the remaining 10 MEUR under the terms of the loan through a share issue between Q3'22-Q1'23. If the offering is completed, we estimate that the offering will be executed at a discount of around 10%. The latest offering was completed at the market price.
A third potential source of funding for the company is global or regional collaboration agreements with large pharmaceutical companies. We believe this would be relevant for Phase II/III trials, where the partner would bear part of the cost of the trial and, once the drug is on the market, would handle its sales, marketing and distribution. Faron's first Phase II/III trial is MATINS, which is investigating the efficacy of BEX as a monotherapy in patients with end-stage cancer. We consider a collaboration agreement on MATINS to be possible.
However, we believe that the more likely subject of a collaboration agreement is the late-stage BEXCOMBO study (BEX combined with PD-1 inhibitor). Similarly, we see strong potential for an agreement in the next phases of BEXMAB (BEX combined with standard therapy) and BEXLUNG (BEX combined with PD-1 inhibitor).
The commercial potential is therefore very high. In terms of commercialisation, we believe Faron will seek to enter into a collaboration agreement with a large pharmaceutical company.
This would provide Faron with resources for drug development, milestone payments, licensing revenues and access to the partner's global sales, marketing and distribution organisation.
Faron's revenue streams are most likely to start accruing from 2026 and peak in the mid-2030s, before bexmarilimab patents expire. The company's current cash position is sufficient to cover expenses until Q1'23 and we expect the company to issue shares in H2'22H1'23.
A successful issuance would also allow us to raise the debt financing tied to the issue. We also expect the company to actively pursue a development and commercialisation agreement with a larger pharmaceutical company in the near future.
TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, will report unaudited half-year financial results for the six months ended June 30, 2022 on Thursday, August 25, 2022 at 02:00 AM (EDT) / 07:00 AM (BST) / 09:00 AM (EEST).
A virtual briefing and Q&A session for investors, analysts and media will be hosted by Dr. Markku Jalkanen, Chief Executive Officer, and Toni Hänninen, Chief Financial Officer, at 7:00 am (EDT) / 12:00 pm (BST) / 2:00 pm (EEST) on the day of results.
Webcast registration link: https://faron.videosync.fi/2022-halfyear-results
The half-year report, presentation, and a replay of the webcast will be available on the Company's website at www.faron.com/investors
https://ichor.bio/product/bexmarilimab-biosimilar-research-grade/
Or are they buys and one of the big guys are buying up 1 share at a time :)
Hey laplom, Keep buying and you will soon be the big investor :)
Four 5000 share buys.. are they slipping shares back to the naz or is this 40k spent by a large investor?
Wouldn't be surprised if there is a potential large buyer out there who want in below 2 quid and we will start to see some big buys coming in now.
Investing 101, watch out for being scared into selling cheap and then watch your shares get gobbled up and the price rises again.
We still have. Small public float which percentage wise gets smaller everything timo and crew buy more
Google showing 190
Let's face it, the sp fell just below 2 today.. not liking that.
we are now lower than all recent investment, which includes our mates timo, marku and family plus the euro funding..ect..
Is the share price level connected to the over all markets being wacked in the knees and just above by covid, war, inflation, greed and all?
Covgas is correct, we were promised SSV. Maybe we got it at 5 pounds... knowing what I know now I would have sold and bought back now.. which we all would do.
Bottom line, this is a long term play.. not that long if you look at the time lines for phase 3 from the post bellow. Even shorter if on complete phase 2 trails they sell out to big pharma.
Either way, I'm sitting tight and if we drop lower I'm buying more.
I reckon an offer will be on the table once we see complete phase 2 data.
That said if phase 3 is 100 million they may still do this alone. They raised 50 million on their own recently .
The 100 million needed for phase 3 trials seems
small fry money for one of the big pharma to partner or buy out faron. I wonder if they are already in talks with gilead and Pfizer!
" Significant licensing and M&A activity in the macrophage field recently
• • Preclinical/early clinical deals (TREM2, LILRB2) ranging from $100 million upfronts and billiondollar milestones With Phase II data Gilead acquired FortySevenInc for $5 billion and Pfizer Trillium for $2 billion, both targeting CD47 "
All quite on the western front!
Well done. I want to top up but no spare funds ATM also have other shares but not prepared to sell them at a loss yet
Was going to go through the RNSs to see what prices Timo has paid for shares over the past few years.
He probably isn't up at all. But keeps investing more. They guy seems switched on so he must be pretty convinced of the end game here